Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice
P-glycoprotein (P-gp), expressed at the blood-brain barrier (BBB), is critical in preventing brain access to substrate drugs and effluxing amyloid beta (Aβ), a contributor to Alzheimer's disease (AD). Strategies to regulate P-gp expression therefore may impact central nervous system (CNS) drug...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Bog |
Udgivet: |
MDPI AG,
2023-08-01T00:00:00Z.
|
Fag: | |
Online adgang: | Connect to this object online. |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_4dd3f90da69441b3b55e4e3bb31a06e6 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Jae Pyun |e author |
700 | 1 | 0 | |a HuiJing Koay |e author |
700 | 1 | 0 | |a Pranav Runwal |e author |
700 | 1 | 0 | |a Celeste Mawal |e author |
700 | 1 | 0 | |a Ashley I. Bush |e author |
700 | 1 | 0 | |a Yijun Pan |e author |
700 | 1 | 0 | |a Paul S. Donnelly |e author |
700 | 1 | 0 | |a Jennifer L. Short |e author |
700 | 1 | 0 | |a Joseph A. Nicolazzo |e author |
245 | 0 | 0 | |a Cu(ATSM) Increases P-Glycoprotein Expression and Function at the Blood-Brain Barrier in C57BL6/J Mice |
260 | |b MDPI AG, |c 2023-08-01T00:00:00Z. | ||
500 | |a 10.3390/pharmaceutics15082084 | ||
500 | |a 1999-4923 | ||
520 | |a P-glycoprotein (P-gp), expressed at the blood-brain barrier (BBB), is critical in preventing brain access to substrate drugs and effluxing amyloid beta (Aβ), a contributor to Alzheimer's disease (AD). Strategies to regulate P-gp expression therefore may impact central nervous system (CNS) drug delivery and brain Aβ levels. As we have demonstrated that the copper complex copper diacetyl bis(4-methyl-3-thiosemicarbazone) (Cu(ATSM)) increases P-gp expression and function in human brain endothelial cells, the present study assessed the impact of Cu(ATSM) on expression and function of P-gp in mouse brain endothelial cells (mBECs) and capillaries in vivo, as well as in peripheral organs. Isolated mBECs treated with Cu(ATSM) (100 nM for 24 h) exhibited a 1.6-fold increase in P-gp expression and a 20% reduction in accumulation of the P-gp substrate rhodamine 123. Oral administration of Cu(ATSM) (30 mg/kg/day) for 28 days led to a 1.5 & 1.3-fold increase in brain microvascular and hepatic expression of P-gp, respectively, and a 20% reduction in BBB transport of [3H]-digoxin. A metallomic analysis showed a 3.5 and 19.9-fold increase in Cu levels in brain microvessels and livers of Cu(ATSM)-treated mice. Our findings demonstrate that Cu(ATSM) increases P-gp expression and function at the BBB in vivo, with implications for CNS drug delivery and clearance of Aβ in AD. | ||
546 | |a EN | ||
690 | |a blood-brain barrier | ||
690 | |a P-glycoprotein | ||
690 | |a copper | ||
690 | |a bis(thiosemicarbazone) | ||
690 | |a CNS drug delivery | ||
690 | |a Pharmacy and materia medica | ||
690 | |a RS1-441 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pharmaceutics, Vol 15, Iss 8, p 2084 (2023) | |
787 | 0 | |n https://www.mdpi.com/1999-4923/15/8/2084 | |
787 | 0 | |n https://doaj.org/toc/1999-4923 | |
856 | 4 | 1 | |u https://doaj.org/article/4dd3f90da69441b3b55e4e3bb31a06e6 |z Connect to this object online. |